Navigation Links
Randomized Phase III Trial Showed Erbitux Significantly Improved,Secondary Endpoints of Progression-Free Survival and Disease,Control in Metastatic Colorectal Cancer Patients

reactions and cardiopulmonary arrest, visit http://www.ERBITUX.com.

Important Safety Information

Grade 3/4 infusion reactions, rarely with fatal outcome (<1 in 1000), occurred in approximately 3% (46/1485) of patients receiving ERBITUX (Cetuximab) therapy. These reactions are characterized by rapid onset of airway obstruction (bronchospasm, stridor, hoarseness), urticaria, hypotension, and/or cardiac arrest. Severe infusion reactions require immediate and permanent discontinuation of ERBITUX therapy.

Most reactions (90%) were associated with the first infusion of ERBITUX despite the use of prophylactic antihistamines. Caution must be exercised with every ERBITUX infusion as there were patients who experienced their first severe infusion reaction during later infusions. A 1-hour observation period is recommended following the ERBITUX infusion. Longer observation periods may be required in patients who experience infusion reactions.

Cardiopulmonary arrest and/or sudden death occurred in 2% (4/208) of patients with squamous cell carcinoma of the head and neck treated with radiation therapy and ERBITUX as compared to none of 212 patients treated with radiation therapy alone. Fatal events occurred within 1 to 43 days after the last ERBITUX treatment. ERBITUX in combination with radiation therapy should be used with caution in patients with known coronary artery disease, congestive heart failure and arrhythmias. Close monitoring of serum electrolytes, including serum magnesium, potassium, and calcium during and after ERBITUX therapy is recommended.

Severe cases of interstitial lung disease (ILD), which was fatal in one case, occurred in less than 0.5% of 774 patients with advanced colorectal cancer (mCRC) receiving ERBITUX. There was one case of ILD reported in 796 patients with head and neck cancer receiving ERBITUX in clinical studies.

In clinical studies of ERBITUX, dermato
'"/>




Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
2. YM BioSciences Reports AeroLEF Randomized Phase IIb Trial Meets Primary Endpoint in Patients with Post-Surgical Pain
3. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
4. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
5. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
10. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
(Date:1/7/2009)...ANAPOLIS, Jan. 7 Eli Lil...t it received a complete response letter from,the...apine long-acting,injection (LAI) for acute and m...Lilly is continuing to work with the agency on the...s not require any additional clinical trials for t...
(Date:1/7/2009)...K, Md., Jan. 7 ImQuest Life Scienc... IND application to the Food and Drug Administrati...d pyrimidinedione HIV inhibitor IQP-0410. ImQuest ...e first quarter of 2009. IQP-0410 is a novel small... a nonnucleoside reverse transcriptase inhibitor (...
(Date:1/7/2009)...RD, England, January 7 Circassia L... on allergy and critical care, today,announced th...in 2008 with,its ToleroMune(R) anti-allergy techn...uitment for a further phase II clinical trial in c...a, has recruited 120 patients with confirmed,cat ...
(Date:1/6/2009)... N.Y., Jan. 6 In recent controlled...sity of Memphis , scientists found that the patent...he first and only proven ingredient to increase le...reasing blood nitrate/nitrate (NOx) in human subje... enables an increase in blood flow to the skeletal...
Breaking Medicine Technology:FDA Issues a Complete Response Letter for Lilly's Olanzapine LAI for Treatment of Schizophrenia in Adults 2FDA Issues a Complete Response Letter for Lilly's Olanzapine LAI for Treatment of Schizophrenia in Adults 3FDA Issues a Complete Response Letter for Lilly's Olanzapine LAI for Treatment of Schizophrenia in Adults 4FDA Issues a Complete Response Letter for Lilly's Olanzapine LAI for Treatment of Schizophrenia in Adults 5FDA Issues a Complete Response Letter for Lilly's Olanzapine LAI for Treatment of Schizophrenia in Adults 6ImQuest Submits Investigational New Product Application to the Food and Drug Administration to Initiate HIV Therapeutic Clinical Trials with IQP-0410 2Circassia Completes Patient Recruitment for Phase II Clinical Trial of Toleromune(R) Allergy Treatment 2Circassia Completes Patient Recruitment for Phase II Clinical Trial of Toleromune(R) Allergy Treatment 3US Testing Proves Glyc'n Go(TM) Increases NO in the Blood Stream 2Helping Veterans in Our Communities 26117 1Helping Veterans in Our Communities 26117 2Helping Veterans in Our Communities 26117 3Valley Baptist Health System Selects Concuitys ClearContracts to More Accurately Calculate Payments from Managed Care and Government Payers 7524 1Valley Baptist Health System Selects Concuitys ClearContracts to More Accurately Calculate Payments from Managed Care and Government Payers 7524 2Valley Baptist Health System Selects Concuitys ClearContracts to More Accurately Calculate Payments from Managed Care and Government Payers 7524 3Valley Baptist Health System Selects Concuitys ClearContracts to More Accurately Calculate Payments from Managed Care and Government Payers 7524 4Healthy individuals may be at risk for heart disease 26112 1Healthy individuals may be at risk for heart disease 26112 2Big Tobaccos Grip on Colleges and Students Loosens But Still Holding Strong 3A New Report Examines Trends on Campuses 26110 1Big Tobaccos Grip on Colleges and Students Loosens But Still Holding Strong 3A New Report Examines Trends on Campuses 26110 2Big Tobaccos Grip on Colleges and Students Loosens But Still Holding Strong 3A New Report Examines Trends on Campuses 26110 3Big Tobaccos Grip on Colleges and Students Loosens But Still Holding Strong 3A New Report Examines Trends on Campuses 26110 4
...rmacokinetics and Dose Proportionality of,Company,...ceutics,Journal -, LAVAL, QC, June 29, 2007 /PRNew...that it will present a poster discussing the dose,...l at the 3rd,International Forum on Pain Medicine ...nada. , The poster compares two different titratio...
... Development Program for Oral Compounds,to Treat ...WIRE)--July 2, 2007--Alkermes, Inc.,(Nasdaq: ALKS)... a,clinical trial of ALKS 29 in alcohol dependent ...s to move forward with its,development program for...ce. ALKS 29 is a combination of two agents with di...
Other Medicine Technology:Labopharm to Present Poster on Dose Titration of Once-daily,Tramadol at 3rd International Forum on Pain Medicine 2Labopharm to Present Poster on Dose Titration of Once-daily,Tramadol at 3rd International Forum on Pain Medicine 3Alkermes Announces Positive Results from Phase 1/2 Clinical Study,of ALKS 29 2Alkermes Announces Positive Results from Phase 1/2 Clinical Study,of ALKS 29 3Alkermes Announces Positive Results from Phase 1/2 Clinical Study,of ALKS 29 4
(Date:1/8/2009)...Newswire-FirstCall/ -- Medivation, Inc.,(Nasdaq: ...esident and chief,executive officer, will present...ence on Wednesday, January 14, at 10:00 a.m. Pacif...ancisco. , Dr. Hung will provide an overvie...rams for Dimebon for Alzheimer,s and Huntington,s ...
(Date:1/8/2009)...g traditional risk factors, experts say , ...ular signs -- or "biomarkers" -- of inflammation m...s a person,s risk of stroke, new research says. ,...these markers does not change things much," said s...t the Methodist DeBakey Heart & Vascular Cente...
(Date:1/8/2009)...wswire-FirstCall/ -- Heska Corporation (Nasdaq: ... What: Heska Corporation Invites You to Joi...008 Earnings Conference Call on the Web, Whe..., Where: www.heska.com (click on the Q4 and ... the front page of this website)., How: ...
(Date:1/8/2009)...ter Healthcare Corporation will create a multidisc... entities announced today. , Under the three-yea...ollaboration projects at Northwestern. Funding lev...on, and Baxter will determine specific project fun...Baxter,s diversified business model, activities wi...
Breaking Medicine News(10 mins):Health News:Medivation Announces Participation in 27th Annual J.P. Morgan Healthcare Conference 2Health News:Inflammation Markers May Help Predict Stroke Risk 2Health News:Inflammation Markers May Help Predict Stroke Risk 3Health News:Webcast Alert: Heska Announces Fourth Quarter and Year-End 2008 Earnings Conference Call Webcast 2Health News:Baxter and Northwestern University partner to target new life sciences projects 2
... is the fastest growing disability in the United S...ch up. One out// of every 166 children is diagnose...c cancer, diabetes and AIDS combined. The Autism ... and Training (ASSERT) program at Utah State Unive...
... looking to lose those extra pounds have been told...ill bring about the best results//. Not so, says n...s effective as dieting plus exercise. The key is i...t calories can be lost effectively by either dieta...
...ing to a latest study, blood letting in patients w...f carried out at a young age//. This finding was p...merican Medical Association. Iron deposit in the ...eloping heart ailments. Hence reducing iron from t...
...from Naples, New York who was diagnosed with lung ...enk who is a former Marine// is currently sufferin...ven him a year or at the maximum eighteen months o...his lottery. But the irony that is accompanying th...
Other Medicine News:Health News:Autism Expert Creates Innovative Intervention Program 2Health News:Autism Expert Creates Innovative Intervention Program 3Health News:Shedding Pounds from Diet or Exercise—Take Your Pic 2Health News:Shedding Pounds from Diet or Exercise—Take Your Pic 3
5x6mm Loop, 2 Irrigation Ports at 10, 2 O'Clock, 18 Gauge Thin Walled 1.2mm Shaft; overall length 40mm; stainless steel
A long, thick-walled cannula which contains a coaxial 12 Fr cannula pre-loaded with a Dotter Helical Loop Basket and a Tip Deflecting Wire Guide. The pre-loaded cannula passes through the outer cannu
...gery is a non-invasive, virtually pain-free altern... radiotherapy for selected indications. With Lekse...ng and patient positioning improves the ability to...arget. This allows a more selective irradiation an...
Clinac Platinum Plus accelerators offer all the high performance features of the EX series and come with the latest high-precision dose sculpting technology for advanced tumor control.
Medicine Products: